GGrantIndex
← Search

Shared Resource: High Throughput Screening Facility

$81,578P30FY2018CANIH

Research Inst Of Fox Chase Can Ctr, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

CELLULAR/MOLECULAR ANALYSES SHARED RESOURCE: HIGH THROUGHPUT SCREENING FACILITY (HTSF) PROJECT SUMMARY/ ABSTRACT The High Throughput Screening Facility (HTSF) provides screening platforms and specialized instrumentation for increased experimental throughput to support the research of Cancer Center members. The HTSF provides the capability to perform hypothesis-generating discovery research with the major goal of generating insights that can be pre-clinically and clinically advanced. Under the direction of Erica Golemis, PhD (MT), the HTSF has 1.0 FTE of staff, that provides access to specialized equipment, expertise, and direct services that enable investigators to address novel areas of translational research that would be difficult or impossible to pursue without the liquid handling, assay resources, reagents and experience of the HTSF. In particular, the HTSF allows investigators to utilize RNAi and compound libraries, and the specialized instrumentation required for large scale screening with these resources. 27 Cancer Center members used the HTSF in calendar year 2014. 90% of equipment hours logged in the HTSF during 2014 were in support of peer-review funded research. 47 Cancer Center members from all 5 Research Programs used the HTSF in the period 2011-2014. The experience of the Facility Director, Golemis, is key in implementing state-of-the-art technology and new approaches. Golemis' leadership coupled with institutional commitment of $40,000 facilitated an upgrade to the server supporting the ImageXpress Micro automated microscope. Due to the complexity, cost and caliber of the instrumentation, HTSF services are best facilitated though a centralized Shared Resource. It would be cost prohibitive to provide each individual research lab the specialized instrumentation available in the HTSF. Cost analysis has demonstrated that certain types of screens would be 4 to 5 times more expensive when outsourced to a commercial vendor. The HTSF Manager has been instrumental to this facility since its inception, and continues to provide stable and expert guidance. The ability to leverage the scientific expertise of the investigators' laboratory in conjunction with the HTSF technical expertise has allowed for cost-effective and high quality screening results. Beyond the context of screening, in support of work to establish clinical correlates or novel technical capabilities, the HTSF works with individual investigators to perform assay development and execute specific projects requiring wet-bench capacity. This combination of resources maximizes the utilization of the equipment and expertise housed within the HTSF to advance the research of Cancer Center members. The HTSF is supported by a Facility Advisory Committee (FAC) that meets at least annually. Recommendations from the FAC are directed to a governing Facility Parent Oversight Committee that serves to ensure that the HTSF continues to have resources necessary to provide the highest quality services for Cancer Center members. Demand for services is expected to increase in the next cycle of the CCSG due to plans to recruit in all 5 Programs, and new demand from Cancer Center members at TU.

View original record on NIH RePORTER →